Reach Us +44-1764-910199
The Pathogenesis and Treatments of Diabetes, A New Insight | OMICS International
ISSN: 2379-1764
Advanced Techniques in Biology & Medicine
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Pathogenesis and Treatments of Diabetes, A New Insight

Da-Yong Lu1*, Jin-Yu Che2, Hong-Ying Wu3and Ting-Ren Lu3

1School of Life Sciences, Shanghai University, 99 Shangda Road, Shanghai200444, PR China

2Shanghai University, 99 Shangda Road, Shanghai200444, PR China

3College of Science, Shanghai University, 99 Shangda Road, Shanghai200444, PR China

Corresponding Author:
Da-Yong Lu
School of Life Sciences
Shanghai University
99 Shangda Road
Shanghai200444, PR China
Tel: 769768586
E-mail: [email protected]

Received date: October 14, 2014; Accepted date: October 21, 2014; Published date: October 30, 2014

Citation: Lu DY, Che JY, Wu HY, Lu TR (2014) The Pathogenesis and Treatments of Diabetes, A New Insight. Adv Tech Biol Med 2:e102. doi:10.4172/2379-1764.1000e102

Copyright: © 2014 Lu DY. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Advanced Techniques in Biology & Medicine


Diabetes Mellitus is an old disease but modern epidemics. Despite many improvements and benefits of diabetes mellitus treatments recently, many new and unresolved problems relevant to diabetes mellitus pathogenesis and therapy have been found; in this editorial, new ideas for building update diabetes mellitus therapeutic systems, new drug development pipelines and experimental and clinical models are addressed.


Diabetes mellitus; Diabetes therapy; Insulin; Insulin-derivatives; Diabetes complications; Small molecular chemical; Bee extract; Cardiovascular complication; Hyperglycemia; Drug toxicity; Propolis; Genetics; Genomics; Pharmacogenomics; Nephropathy; Traditional chinese medicine


Diabetes Mellitus is an old disease but modern epidemics. The epidemics of diabetes in China, developing and developed countries have been growing now. For this reason, medical expenses on diabetes diagnosis and treatments have been increased greatly worldwide now [1,2]. Many people of experienced medical personnel and many new comers all enthuse for diabetes studies. Owing to the diversity of talents and educational backgrounds of researchers, scientific merits and usefulness of experimental or clinical study have been differed greatly. This editorial will address some of them.

Building Good Educational Systems Worldwides

Developing to type 2 diabetes mellitus might undergo a long course of pathogenesis processes in susceptible human (many of them are family inherence). Many preventive measures or control food intake can slow the disease progression and reduce morbidity rates. Some good and long-term educations, propaganda and wide-spread the basic knowledge and themes of diabetes pathogenesis and therapeutics will be beneficial to people’ healthy quality.

Therapeutic Studies

Development of more effective and less toxic drugs is always the ultimate goals of drug developments and manufactures. Likelihood, it is one of the major avenues of diabetes mellitus treatment study and clinical applications [3-8]. Despite insulin and insulin-derivatives are the safest and first-line anti-hyperglycemia therapeutic options and can be used in both type I and type II diabetes mellitus patients, it also has some obvious deficiency. The most conspicuous one is that needle injection is needed every day, which leads to treatment inconvenience and physical burden for diabetes mellitus patients. Currently, oral intake of drugs is the most welcoming and environmental-friendly drug administration options for all patients. Thus, some small-molecular chemicals having the insulin-configurations or insulin receptors binding activity might be potential oral anti-hyperglycemia drugs for surrogating insulin or insulin-derivatives. In future, we can compare, simulate and calculate insulin-configurations or insulin receptors binding activity from large-pool of small-molecular chemicals pipelines by computing or experimental work.

Seeking solutions outside of normal therapeutic arsenals, such as propolis is also good options [9]. Propolis is bee extracts of waxy-like and other components. It has been discovered for anti-bacterial, antifungal or anti-tumors [9]. In China, it has been licensed as healthypromoting agents. Now it has been largely sold for treatment of diabetes mellitus and received widely acclaiming for its efficacy in China. Many renowned-brands of long history Chinese Pharmaceutical Companies are almost all manufactured and sold propolis widely. Nonetheless, large-scale, double-blind systematic clinical investigations are needed in future. Some similar alterations should also be initiated, cooperatively studied, testified and verified by more experimental, preclinical or clinical investigations worldwide (Table 1).

Targets Mechanisms Personal opinions
Glucose Decrease glucose concentrations in animal and human by many metabolism interference
Substitute food glucose intake with other mono carbohydrates 
Controversy Controversy
Insulin Human insulin and its derivatives
Modulators of pancreatic island ß-cell
First line therapy
Disease complications Cardiovascular complications
Vision impairment
Mental retardations
Chronic leg infection
Potential and need to be improved
Hepatic functions Ameliorate of damaged cells and metabolism Future trend

Table 1: Current targets and mechanisms of different drugs for diabetes mellitus treatments

Future Directions

Since a lot of people are agonized and suffered with hyperglycemia and related complications worldwide, current diabetes mellitus therapy needs to be improved. Many persistent efforts and novel ideas are all welcomed. Table 2 illustrates roadmap and many avenues for diabetes mellitus treatment study and clinical usefulness in future.

Development and production of more effective and low toxicity anti-hyperglycemia chemical drugs
Educate more normal people to understand the basic knowledge of diabetes. So diabetes mellitus can be properly noticed and treated once the disease just begins.
To deepen fundamental and comprehensive mechanism study to make licensed anti-hyperglycemia drugs more reliable and versatility
Genetic or molecular study of pathogenesis of disease progression, drug pharmacological mechanisms of action and drug toxicities in living bodies along with different individuals, ethnic groups and largest populations.
Lesson from history—traditional Chinese medicine, Indian medicine or Middle-east medicine etc
Perfecting the personalized diabetes therapy (PDT) study and applications
To test and study some new initiatives and natural products such as propolis
To set a more rigorous toxicity baseline for anti-hyperglycemia drugs development, approval and license in developing countries, or even in developed countries.
To find some small-molecular chemicals for simulating insulin functions and receptors-binding activities

Table 2: Possible roadmap and landscape for future anti-hyperglycemia study Adapted and modified from ref 3.


In future, new challenges relating to improve therapeutic outcomes for late-staged diabetes mellitus patients are urgently needed. In addition, personal diabetes treatment might be also useful and perfected by persistent experimental and clinical investigations and systematic studies.


This work was funded by Shanghai Science and Technology Foundation of High Educations 97A49


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 12018
  • [From(publication date):
    December-2014 - Jan 20, 2019]
  • Breakdown by view type
  • HTML page views : 8205
  • PDF downloads : 3813

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2019-20
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

ankara escort

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

pendik escort

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2019 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version